<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091010</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Alcoholic Hepatitis-01</org_study_id>
    <nct_id>NCT03091010</nct_id>
  </id_info>
  <brief_title>A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis.</brief_title>
  <official_title>A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study population: Patients attending the Out Patient Department and admitted to Institute of&#xD;
      Liver and Biliary Sciences.&#xD;
&#xD;
      Study design: Prospective randomized controlled trial Study period: One year- January 2017-&#xD;
      December 2018 Sample size: 130 (65 cases in each group) Intervention: The subjects will be&#xD;
      given Fecal Microbiota Transplantation through a NJ tube placed after admission to the&#xD;
      hospital. Participants will be administered the processed fecal microbiota sample collected&#xD;
      from a related or unrelated healthy donor for a period of 7 days.&#xD;
&#xD;
      Monitoring and assessment:&#xD;
&#xD;
      The recipient will be monitored every day after Fecal Microbiota Transplantation therapy.&#xD;
&#xD;
      The recipient will undergo physical examination, complete blood counts, at baseline and a&#xD;
      chest X ray, serum procalcitonin, CRP and Tumor Necrosis Factor alpha levels, Liver Function&#xD;
      Tests, Kidney Function Tests, International Normalized Ratio and arterial ammonia, at day&#xD;
      0,4,7,14,28,90,180,270 and 365 from the start of therapy.&#xD;
&#xD;
      Microbiota analysis of the donors will be done at baseline and the recipients will be done on&#xD;
      day 0,7,28,90 &amp; 180.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 8, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 24, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with Overall Survival at 3 months</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Child Pugh Turcotte (score) severity in both groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Model for End Stage Liver Disease (MELD) of liver disease severity in both groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Glasgow Alcoholic Hepatitis (score) in both groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Maddrey's Discriminant Function (score) in both groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in both groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Severe Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days</description>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis</description>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with severe alcoholic hepatitis .&#xD;
&#xD;
          -  Eligible for steroid therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Upper gastrointestinal bleed within the past one month.&#xD;
&#xD;
          -  Active sepsis&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 mg/dl (Hepato renal syndrome)&#xD;
&#xD;
          -  Intestinal paralysis&#xD;
&#xD;
          -  Hepatic or extrahepatic malignancy&#xD;
&#xD;
          -  Disseminated intravascular coagulation&#xD;
&#xD;
          -  Discriminant Function (DF) &gt;90&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

